Metrics as of 10/13/2026, 06:50 PM (Berlin time), refresh in progress.
Eikon Therapeutics Stock
Eikon Therapeutics, Inc. Common Stock
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Roger Perlmutter
- Employees
- 384
- Market cap
- $378 M
- IPO
- 05/02/2026
- Web
- eikontx.com
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of…
Eikon Therapeutics stock: price history
1D
-4.3%
1W
-7.5%
1M
-22.3%
6M
-34.5%
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~13% stronger price swings than usual
Ask the agents about Eikon Therapeutics
Analyst assessment of Eikon Therapeutics
PRICE TARGET LOW
US$5.00
CONSENSUS
US$5.00
MEDIAN
US$5.00
PRICE TARGET HIGH
US$5.00
0
STRONG BUY
0
BUY
0
HOLD
1
SELL
0
STRONG SELL
1
TOTAL · Sell
As of: 14/08/2026
Eikon Therapeutics stock metrics
P/E
-1.51
P/B
0.81
EV/EBITDA
-1.64
RETURN ON EQUITY
-19.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.54
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
1,011.3%
FLOAT SHARES
547,505,569
AVG. DAILY VOLUME (30D)
616,754
Insider transactions (SEC)
Column Group IV GP, LP
Institutional holders
Comparable stocks
Frequently asked questions about Eikon Therapeutics stock
What does Eikon Therapeutics do?
Eikon Therapeutics, Inc. Common Stock is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Roger Perlmutter, the company employs around 384 people.
The IPO was on 05/02/2026; the stock trades on NASDAQ under the ticker EIKN.
What do analysts say about Eikon Therapeutics stock?
1 analysts rate the stock, the consensus is Sell (as of 14/08/2026).
The average price target is US$5.00, ranging from US$5.00 to US$5.00, with a median of US$5.00.
This is an external assessment, not a statement by Market Jury.
When does Eikon Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 13% stronger than usual.
Does Eikon Therapeutics pay a dividend?
No, Eikon Therapeutics currently does not pay a dividend.
Which stocks are comparable to Eikon Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Eikon Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Eikon Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.